MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.trre.2023.100795

Медицинская библиотека · Transplantation reviews (Orlando, Fla.) · 2023

The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis.

Montero Nuria, Rodrigo Emilio, Crespo Marta, Cruzado Josep M, Gutierrez-Dalmau Alex, Mazuecos Auxiliadora, Sancho Asunción, Belmar Lara, Calatayud Emma, Mora Paula, Oliveras Laia, Solà Eulalia, Villanego Florentino, Pascual Julio

МетаанализСистематический обзорСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Recommendations of the use of antibody induction treatments in kidney transplant recipients (KTR) are based on moderate quality and historical studies. This systematic review aims to reevaluate, based on actual studies, the effects of different antibody preparations when used in specific KTR subgroups.

METHODS

We searched MEDLINE and CENTRAL and selected randomized controlled trials (RCT) and observational studies looking at different antibody preparations used as induction in KTR. Comparisons were categorized into different KTR subgroups: standard, high risk of rejection, high risk of delayed graft function (DGF), living donor, and elderly KTR. Two authors independently assessed the risk of bias.

RESULTS

Thirty-seven RCT and 99 observational studies were finally included. Compared to anti-interleukin-2-receptor antibodies (IL2RA), anti-thymocyte globulin (ATG) reduced the risk of acute rejection at two years in standard KTR (RR 0.74, 95%CI 0.61-0.89) and high risk of rejection KTR (RR 0.55, 95%CI 0.43-0.72), but without decreasing the risk of graft loss. We did not find significant differences comparing ATG vs. alemtuzumab or different ATG dosages in any KTR group.

CONCLUSIONS

Despite many studies carried out on induction treatment in KTR, their heterogeneity and short follow-up preclude definitive conclusions to determine the optimal induction therapy. Compared with IL2RA, ATG reduced rejection in standard-risk, highly sensitized, and living donor graft recipients, but not in high DGF risk or elderly recipients. More studies are needed to demonstrate beneficial effects in other KTR subgroups and overall patient and graft survival.

Для цитирования: Montero Nuria, Rodrigo Emilio, Crespo Marta, Cruzado Josep M, Gutierrez-Dalmau Alex, Mazuecos Auxiliadora, Sancho Asunción, Belmar Lara, Calatayud Emma, Mora Paula, Oliveras Laia, Solà Eulalia, Villanego Florentino, Pascual Julio. The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis.. Transplantation reviews (Orlando, Fla.). 2023. DOI: 10.1016/j.trre.2023.100795.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.